camrelizumab + placebo

Camrelizumab + placebo refers to a combination used in clinical trials where one group receives camrelizumab and the other receives a placebo for comparison. Camrelizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells, B cells, and natural killer cells. By blocking PD-1 from binding to its ligand PD-L1 on tumor cells, camrelizumab prevents immune evasion by cancer and enhances anti-tumor immune responses. It is primarily developed for various cancers including hepatocellular carcinoma, Hodgkin lymphoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, and non-small cell lung cancer[1][3][4][5]. The "placebo" component is an inactive substance used as a control in randomized controlled trials.